BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29185118)

  • 1. Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Trentham-Dietz A; Ergun MA; Alagoz O; Stout NK; Gangnon RE; Hampton JM; Dittus K; James TA; Vacek PM; Herschorn SD; Burnside ES; Tosteson ANA; Weaver DL; Sprague BL
    Breast Cancer Res Treat; 2018 Feb; 168(1):229-239. PubMed ID: 29185118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
    Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective cost-effectiveness analysis of screening mammography.
    Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
    J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study.
    Kuhl CK; Schrading S; Bieling HB; Wardelmann E; Leutner CC; Koenig R; Kuhn W; Schild HH
    Lancet; 2007 Aug; 370(9586):485-92. PubMed ID: 17693177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital mammography screening: weighing reduced mortality against increased overdiagnosis.
    de Gelder R; Fracheboud J; Heijnsdijk EA; den Heeten G; Verbeek AL; Broeders MJ; Draisma G; de Koning HJ
    Prev Med; 2011 Sep; 53(3):134-40. PubMed ID: 21718717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
    Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
    Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
    Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
    Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort.
    Puvanesarajah S; Gapstur SM; Gansler T; Sherman ME; Patel AV; Gaudet MM
    Cancer Causes Control; 2020 Jan; 31(1):95-103. PubMed ID: 31802322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
    Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
    Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?
    Daroles J; Borget I; Suciu V; Mazouni C; Delaloge S; Balleyguier C
    Eur J Cancer; 2017 Nov; 85():23-30. PubMed ID: 28881248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection Rates of Ductal Carcinoma in Situ with Biennial Digital Mammography Screening: Radiologic Findings Support Pathologic Model of Tumor Progression.
    Weigel S; Khil L; Hense HW; Decker T; Wellmann J; Heidrich J; Sommer A; Heidinger O; Heindel W
    Radiology; 2018 Feb; 286(2):424-432. PubMed ID: 29106821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic sensitivity of dynamic contrast-enhanced magnetic resonance imaging and breast-specific gamma imaging in women with calcified and non-calcified DCIS.
    Kim JS; Lee SM; Cha ES
    Acta Radiol; 2014 Jul; 55(6):668-75. PubMed ID: 24043881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
    van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
    Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
    Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
    J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.
    Warner E; Causer PA; Wong JW; Wright FC; Jong RA; Hill KA; Messner SJ; Yaffe MJ; Narod SA; Plewes DB
    Breast J; 2011; 17(1):9-17. PubMed ID: 21251121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.